NatureAugust 3, 2026
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns
Reported by Nature. Read the original →
What the story says
The headline reports that Semaglutide is linked to improvements in stiffness and offers various benefits for the liver, with these effects showing different patterns based on dosage and weight.
Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
SemaglutideA · Human clinical
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
What the headline doesn't tell you
- Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.